We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Madrigal Pharmaceuticals Inc (MDGL) USD0.00010

Sell:$236.98 Buy:$237.69 Change: $16.83 (6.62%)
NASDAQ:0.55%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$236.98
Buy:$237.69
Change: $16.83 (6.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$236.98
Buy:$237.69
Change: $16.83 (6.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Contact details

Address:
200 Barr Harbor Dr Ste 400
WEST CONSHOHOCKEN
19428-2978
United States
Telephone:
+1 (404) 3809263
Website:
https://www.madrigalpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MDGL
ISIN:
US5588681057
Market cap:
$4.73 billion
Shares in issue:
19.74 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Bill Sibold
    President, Chief Executive Officer, Director
  • Alex Howarth
    Chief Financial Officer, Senior Vice President
  • Rebecca Taub
    President of Research and Development, Chief Medical Officer, Director
  • Brian Lynch
    Senior Vice President, General Counsel
  • Ronald Filippo
    Chief Information Officer
  • Carole Huntsman
    Chief Commercial Officer
  • Robert Waltermire
    Chief Pharmaceutical Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.